Abid Oueslati

4.8k total citations · 1 hit paper
39 papers, 3.6k citations indexed

About

Abid Oueslati is a scholar working on Neurology, Cellular and Molecular Neuroscience and Molecular Biology. According to data from OpenAlex, Abid Oueslati has authored 39 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Neurology, 24 papers in Cellular and Molecular Neuroscience and 11 papers in Molecular Biology. Recurrent topics in Abid Oueslati's work include Parkinson's Disease Mechanisms and Treatments (22 papers), Neurological disorders and treatments (16 papers) and Genetic Neurodegenerative Diseases (13 papers). Abid Oueslati is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (22 papers), Neurological disorders and treatments (16 papers) and Genetic Neurodegenerative Diseases (13 papers). Abid Oueslati collaborates with scholars based in Canada, Switzerland and United States. Abid Oueslati's co-authors include Hilal A. Lashuel, Eliezer Masliah, Cassia Overk, Margot Fournier, Patrick Aebischer, Bernard L. Schneider, Katerina E. Paleologou, David Eliezer, Markus Zweckstetter and Martial Mbefo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Neuroscience.

In The Last Decade

Abid Oueslati

37 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The many faces of α-synuclein: from structure and toxicity to therapeutic target

2012 1.3k citations Hilal A. Lashuel, Cassia Overk et al. Nature reviews. Neuroscience profile →

Peers

Countries citing papers authored by Abid Oueslati

Since Specialization

Citations

This map shows the geographic impact of Abid Oueslati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abid Oueslati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abid Oueslati more than expected).

Fields of papers citing papers by Abid Oueslati

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Abid Oueslati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abid Oueslati. The network helps show where Abid Oueslati may publish in the future.

Co-authorship network of co-authors of Abid Oueslati

This figure shows the co-authorship network connecting the top 25 collaborators of Abid Oueslati. A scholar is included among the top collaborators of Abid Oueslati based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Abid Oueslati. Abid Oueslati is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Combining light-induced aggregation and biotin proximity labeling implicates endolysosomal proteins in early α-synuclein oligomerization 2025 ·iScience ·Maxime Teixeira, Razan Sheta, (unknown), (unknown), Jérémy Loehr, Jean‐Philippe Lambert, Abid Oueslati	0
2	Interplay between lipid droplets and alpha-synuclein: implication in Parkinson’s disease pathogenesis 2025 ·Frontiers in Molecular Neuroscience ·(unknown), Razan Sheta, Abid Oueslati	0
3	Pharmacological inhibition of PLK2 kinase activity mitigates cognitive decline but aggravates APP pathology in a sex-dependent manner in APP/PS1 mouse model of Alzheimer's disease 2024 ·Heliyon ·(unknown), (unknown), (unknown), Serge Rivest, Abid Oueslati	1
4	Behavioral analysis of motor and non-motor impairment in rodent models of Parkinson's disease 2024 ·Frontiers in Aging Neuroscience ·Razan Sheta, (unknown), (unknown), (unknown), Abid Oueslati	4
5	Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson’s disease in rodent brains 2023 ·Molecular Neurodegeneration ·(unknown), (unknown), Razan Sheta, Omar M. A. El‐Agnaf, Abid Oueslati	4
6	Aggregation of alpha-synuclein disrupts mitochondrial metabolism and induce mitophagy via cardiolipin externalization 2023 ·Cell Death and Disease ·(unknown), (unknown), Mehtab Khan, Razan Sheta, Stéphanie Jean, (unknown), Maxime Teixeira, (unknown), Isabelle Perron, Abid Oueslati, Étienne Hébert-Chatelain	35
7	Optogenetic-mediated induction and monitoring of α-synuclein aggregation in cellular models of Parkinson’s disease 2023 ·STAR Protocols ·Maxime Teixeira, Razan Sheta, (unknown), Abid Oueslati	1
8	Optimized protocol for the generation of functional human induced-pluripotent-stem-cell-derived dopaminergic neurons 2023 ·STAR Protocols ·Razan Sheta, Maxime Teixeira, (unknown), Abid Oueslati	7
9	Inhibition of PLK2 activity affects APP and tau pathology and improves synaptic content in a sex-dependent manner in a 3xTg mouse model of Alzheimer's disease 2022 ·Neurobiology of Disease ·(unknown), Razan Sheta, (unknown), (unknown), Cyntia Tremblay, Frédéric Calon, Serge Rivest, Abid Oueslati	9
10	Evidence for the spread of human-derived mutant huntingtin protein in mice and non-human primates 2020 ·Neurobiology of Disease ·(unknown), (unknown), Melanie Alpaugh, Ludivine S. Breger, Benjamin Dehay, Tao Zhu, Ling Zhang, Chuan Qin, Giulia Cisbani, (unknown), Jean‐Paul G. Vonsattel, Steve Lacroix, Abid Oueslati, Erwan Bézard, Francesca Cicchetti	13
11	Inhibiting cellular uptake of mutant huntingtin using a monoclonal antibody: Implications for the treatment of Huntington's disease 2020 ·Neurobiology of Disease ·Stefan Bartl, Abid Oueslati, Amber L. Southwell, (unknown), (unknown), Linda Suzanne David, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Guenther Staffler, Michael R. Hayden, Francesca Cicchetti, Oskar W. Smrzka	13
12	Dissecting the Molecular Pathway Involved in PLK2 Kinase-mediated α-Synuclein-selective Autophagic Degradation 2017 ·Journal of Biological Chemistry ·(unknown), (unknown), Abid Oueslati	28
13	Parkinson Disease Mutant E46K Enhances α-Synuclein Phosphorylation in Mammalian Cell Lines, in Yeast, and in Vivo 2015 ·Journal of Biological Chemistry ·Martial Mbefo, Mohamed-Bilal Fares, Katerina E. Paleologou, Abid Oueslati, Guowei Yin, Sandra Tenreiro, Madalena Pinto, Tiago F. Outeiro, Markus Zweckstetter, Eliezer Masliah, Hilal A. Lashuel	48
14	The many faces of α-synuclein: from structure and toxicity to therapeutic target breakdown → 2012 ·Nature reviews. Neuroscience ·Hilal A. Lashuel, Cassia Overk, Abid Oueslati, Eliezer Masliah	1254
15	Phosphorylation at S87 Is Enhanced in Synucleinopathies, Inhibits α-Synuclein Oligomerization, and Influences Synuclein-Membrane Interactions 2010 ·Journal of Neuroscience ·Katerina E. Paleologou, Abid Oueslati, (unknown), Carla C. Rospigliosi, Hai‐Young Kim, (unknown), Claudio O. Fernández, Adrien W. Schmid, Fariba Chegini, Wei Gai, Diego Chiappe, Marc Moniatte, Bernard L. Schneider, Patrick Aebischer, David Eliezer, Markus Zweckstetter, Eliezer Masliah, Hilal A. Lashuel	262
16	Role of post-translational modifications in modulating the structure, function and toxicity of α-synuclein 2010 ·Progress in brain research ·Abid Oueslati, Margot Fournier, Hilal A. Lashuel	269
17	Phosphorylation of Synucleins by Members of the Polo-like Kinase Family 2009 ·Journal of Biological Chemistry ·Martial Mbefo, Katerina E. Paleologou, Ahmed Boucharaba, Abid Oueslati, Heinrich Schell, Margot Fournier, Diana Olschewski, Guowei Yin, Markus Zweckstetter, Eliezer Masliah, Philipp J. Kahle, Harald Hirling, Hilal A. Lashuel	205
18	Different functional basal ganglia subcircuits associated with anti-akinetic and dyskinesiogenic effects of antiparkinsonian therapies 2009 ·Neurobiology of Disease ·(unknown), (unknown), Christophe Melon, Abid Oueslati, Lydia Kerkerian‐Le Goff, Pascal Salin	20
19	Chronic high‐frequency stimulation of the subthalamic nucleus and L‐DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission 2006 ·European Journal of Neuroscience ·Paolo Gubellini, Alexandre Eusébio, Abid Oueslati, Christophe Melon, Lydia Kerkerian‐Le Goff, Pascal Salin	70
20	Dysfunction of the cortico‐basal ganglia‐cortical loop in a rat model of early parkinsonism is reversed by metabotropic glutamate receptor 5 antagonism 2005 ·European Journal of Neuroscience ·Abid Oueslati, Nathalie Breysse, Marianne Amalric, Lydia Kerkerian‐Le Goff, Pascal Salin	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact